PTCT241220C28000
- 0.00
- 0.000.00%
PTC Therapeutics Newsroom
RBC Capital Remains a Hold on PTC Therapeutics (PTCT)
Baird Maintains PTC Therapeutics(PTCT.US) With Buy Rating, Raises Target Price to $52
Baird Maintains Outperform on PTC Therapeutics, Raises Price Target to $52
TD Cowen Remains a Hold on PTC Therapeutics (PTCT)
BofA Securities Maintains PTC Therapeutics(PTCT.US) With Sell Rating, Announces Target Price $31
PTC Therapeutics: Sell Rating Due to Unmet Trial Goals and Overvaluation Concerns
William Blair Maintains PTC Therapeutics(PTCT.US) With Buy Rating
PTC Therapeutics Is Maintained at Overweight by Wells Fargo
PTC Therapeutics Analyst Ratings
Wells Fargo Maintains PTC Therapeutics(PTCT.US) With Buy Rating, Raises Target Price to $68
J.P. Morgan Maintains PTC Therapeutics(PTCT.US) With Buy Rating, Raises Target Price to $62
PTC Therapeutics Is Maintained at Equal-Weight by Barclays
PTC Therapeutics Analyst Ratings
Barclays Maintains PTC Therapeutics(PTCT.US) With Hold Rating, Raises Target Price to $45
Analysts Have Conflicting Sentiments on These Healthcare Companies: PTC Therapeutics (PTCT), Medtronic (MDT) and OptimizeRx (OPRX)
William Blair Maintains PTC Therapeutics(PTCT.US) With Buy Rating
PTC Therapeutics Gains Buy Rating Following FDA Approval of Groundbreaking Gene Therapy Kebilidi
Balancing Growth Prospects and Regulatory Challenges: A Hold Rating on PTC Therapeutics
PTC Therapeutics (PTCT) Receives a Hold From Barclays
A Quick Look at Today's Ratings for PTC Therapeutics(PTCT.US), With a Forecast Between $45 to $48